Report cover image

Interleukin-18 (IL-18) Inhibitor - Pipeline Insight, 2024

Publisher DelveInsight
Published Apr 01, 2024
Length 60 Pages
SKU # DEL18679680

Description

Interleukin-18 (IL-18) Inhibitor - Pipeline Insight, 2024



DelveInsight’s, “Interleukin-18 (IL-18) Inhibitor - Pipeline Insight, 2024” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Interleukin-18 (IL-18) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Interleukin-18 (IL-18) Inhibitor: Understanding

Interleukin-18 (IL-18) Inhibitor: Overview

Interleukin-18 (IL-18) is a potent pro-inflammatory cytokine involved in host defense against infections and regulates the innate and acquired immune response. IL-18 is produced by both hematopoietic and non-hematopoietic cells, including monocytes, macrophages, keratinocytes and mesenchymal cell. IL-18 could potentially induce inflammatory and cytotoxic immune cell activities leading to autoimmunity. Its elevated levels have been reported in the blood of patients with some immune-related diseases, including rheumatoid arthritis, systemic lupus erythematosus, type I diabetes mellitus, atopic dermatitis, psoriasis, and inflammatory bowel disease. The broad biological role of the IL-18 cytokine on immune cells have revealed its potential role in inflammatory and autoimmune diseases. IL-18 have been shown to be a diagnostic marker and predictor of inflammatory conditions like myocardial ischemia, acute respiratory distress syndrome , chronic obstructive pulmonary disease, post infectious bronchiolitis obliterans and sepsis-induced multi organ injury. IL-18 has also received increase attention in the pathophysiology of neuro-vascular diseases such as in intracerebral hemorrhage, Japanese encephalitis, ocular Behcet disease, abdominal aortic aneurysm, amyotrophic lateral sclerosis, and glioma and most interestingly in cognitive impairment and agitation in severe mental disease.

Due to the biological properties of IL-18 and its pathological role in different diseases, it is not surprising that drug discovery and therapies are focused on IL-18 and the control of its more pathological outcomes. Using monoclonal antibodies, IL-18 is prevented by inhibiting its production in cells and its secretion from cells.

“Interleukin-18 (IL-18) Inhibitor - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Interleukin-18 (IL-18) Inhibitor pipeline landscape is provided which includes the disease overview and Interleukin-18 (IL-18) Inhibitor treatment guidelines. The assessment part of the report embraces, in depth Interleukin-18 (IL-18) Inhibitor commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Interleukin-18 (IL-18) Inhibitor collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Interleukin-18 (IL-18) Inhibitor R&D. The therapies under development are focused on novel approaches to treat/improve Interleukin-18 (IL-18) Inhibitor.
Interleukin-18 (IL-18) Inhibitor Emerging Drugs Chapters

This segment of the Interleukin-18 (IL-18) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Interleukin-18 (IL-18) Inhibitor Emerging Drugs
  • Tadekinig alfa: AB2 Bio Ltd.
Tadekinig alfa is a recombinant Interleukin-18 Binding Protein (r-hIL-18BP) with a high affinity for IL-18, a major inflammatory cytokine. In healthy people, there is a large excess of naturally occurring IL-18BP keeping levels of free IL-18 low. However, in patients with certain inflammatory diseases, the IL-18/IL-18BP balance is disrupted, resulting in high levels of free and active IL-18, which in turn leads to pathological inflammation. Administration of AB2 Bio’s exogenous recombinant human IL-18BP restores the IL-18/IL-18BP balance, removing free IL-18 and thereby reducing inflammation. Currently, the drug is in Phase III stage of its clinical trial for the treatment of XIAP Deficiency.
  • GSK-1070806: GlaxoSmithKline
GSK-1070806 is under development for the treatment of Crohn’s disease and moderate to severe atopic dermatitis (AtD). The drug candidate is administered intravenously as a solution and subcutaneous route. GSK-1070806 is a humanized IgG1/kappa antibody which is directed against the soluble cytokine interleukin-18 (IL-18). Currently, the drug is in Phase II stage of its clinical trial for the treatment of Atopic Dermatitis.

Further product details are provided in the report……..

Interleukin-18 (IL-18) Inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different Interleukin-18 (IL-18) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players in Interleukin-18 (IL-18) Inhibitor
There are approx. 4+ key companies which are developing the therapies for Interleukin-18 (IL-18) Inhibitor. The companies which have their Interleukin-18 (IL-18) Inhibitor drug candidates in the most advanced stage, i.e. Phase III include, AB2 Bio Ltd.

Phases

DelveInsight’s report covers around 4+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Interleukin-18 (IL-18) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Oligonucleotide
  • Peptide
  • Small molecule
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Interleukin-18 (IL-18) Inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Interleukin-18 (IL-18) Inhibitor therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interleukin-18 (IL-18) Inhibitor drugs.

Interleukin-18 (IL-18) Inhibitor Report Insights
  • Interleukin-18 (IL-18) Inhibitor Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Interleukin-18 (IL-18) Inhibitor Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Interleukin-18 (IL-18) Inhibitor drugs?
  • How many Interleukin-18 (IL-18) Inhibitor drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Interleukin-18 (IL-18) Inhibitor?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Interleukin-18 (IL-18) Inhibitor therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Interleukin-18 (IL-18) Inhibitor and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • AB2 Bio Ltd.
  • Simcha Therapeutics
  • GlaxoSmithKline
  • Novartis
  • Olatec Therapeutics
  • Compugen
  • Lassen Therapeutics
  • Xencor
  • Bright Peak Therapeutics
  • Werewolf Therapeutics
Key Products
  • Tadekinig alfa
  • ST-067
  • GSK 1070806
  • MAS 825
  • OLT1177
  • COM 503
  • LASN 500
  • XmAb 143
  • BPT 567
  • WTX 518

Table of Contents

60 Pages
Introduction
Executive Summary
Interleukin-18 (IL-18) Inhibitor : Overview
Introduction
Structure
Function
Mechanism of action
AXL as therapeutic target
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Assessment by Product Type
Assessment by Stage and Product Type
Interleukin-18 (IL-18) Inhibitor – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Tadekinig alfa: AB2 Bio Ltd.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
GSK-1070806: GlaxoSmithKline
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Preclinical Stage Products
Comparative Analysis
LASN 500: Lassen Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Interleukin-18 (IL-18) Inhibitor - Collaborations Assessment- Licensing / Partnering / Funding
Interleukin-18 (IL-18) Inhibitor - Unmet Needs
Interleukin-18 (IL-18) Inhibitor - Market Drivers and Barriers
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us